Rani Therapeutics Stock Surges 150% on Oversubscribed Private Placement
Rani Therapeutics (RANI) shares skyrocketed 150% in pre-market trading after announcing a $60.3 million private placement. The clinical-stage biotherapeutics company secured commitments from institutional investors, including Executive Chairman Mir Imran and new backer Samsara, at $0.48 per share.
The deal includes 42.6 million shares and 82.4 million pre-funded warrants, each carrying an additional five-year warrant. Proceeds will advance the company's RaniPill platform pipeline. This capital injection follows a 65% year-to-date decline for the stock, highlighting investor confidence in the company's turnaround potential.